DiaMedica Therapeutics (DMAC) News Today $4.70 +0.52 (+12.44%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Enhanced Prospects for Diamedica Therapeutics with Trial Refinements and New InitiativesNovember 16, 2024 | markets.businessinsider.comDiaMedica Therapeutics (NASDAQ:DMAC) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of DiaMedica Therapeutics in a report on Friday.November 15, 2024 | marketbeat.comDiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comDiaMedica Therapeutics doses first patient in Phase 2 DM199 trialNovember 14, 2024 | markets.businessinsider.comDiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.comDiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of PreeclampsiaNovember 13, 2024 | finance.yahoo.comDiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of PreeclampsiaNovember 13, 2024 | businesswire.comDiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select ConferenceNovember 13, 2024 | finance.yahoo.comPreview: DiaMedica Therapeutics's EarningsNovember 13, 2024 | benzinga.comDiaMedica Therapeutics (DMAC) to Release Earnings on WednesdayDiaMedica Therapeutics (NASDAQ:DMAC) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comDiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024November 6, 2024 | businesswire.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Large Growth in Short InterestDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 152,300 shares, a growth of 10.0% from the September 15th total of 138,400 shares. Based on an average daily trading volume, of 54,000 shares, the days-to-cover ratio is presently 2.8 days.October 15, 2024 | marketbeat.comDiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of PreeclampsiaOctober 9, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. to Post Q3 2024 Earnings of ($0.13) Per Share, HC Wainwright Forecasts (NASDAQ:DMAC)DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings estimates for shares of DiaMedica Therapeutics in a report released on Monday, October 7th. HC Wainwright analyst M. Caufield expects that the company will post earnings ofOctober 9, 2024 | marketbeat.comOptimistic Outlook on DiaMedica Therapeutics’ Market Potential and Clinical AdvancementsOctober 8, 2024 | markets.businessinsider.comDiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$9.05mOctober 8, 2024 | finance.yahoo.comHC Wainwright & Co. Initiates Coverage of DiaMedica Therapeutics (DMAC) with Buy RecommendationOctober 8, 2024 | msn.comDiaMedica Therapeutics (NASDAQ:DMAC) Research Coverage Started at HC WainwrightHC Wainwright began coverage on shares of DiaMedica Therapeutics in a research note on Monday. They issued a "buy" rating and a $7.00 target price for the company.October 7, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 2.7%DiaMedica Therapeutics (NASDAQ:DMAC) Trading 2.7% HigherSeptember 10, 2024 | marketbeat.comDiaMedica Therapeutics Upcoming Conference ParticipationSeptember 5, 2024 | finance.yahoo.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. raised its holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Free Report) by 26.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,013,522 shares of the company's stock after acquiring an additionalAugust 19, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Receives Outperform Rating from OppenheimerOppenheimer reaffirmed an "outperform" rating and issued a $6.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday.August 16, 2024 | marketbeat.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 17.0% in JulyDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 144,200 shares, a decrease of 17.0% from the July 15th total of 173,700 shares. Based on an average daily trading volume, of 60,500 shares, the days-to-cover ratio is presently 2.4 days.August 16, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPSDiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. During the same period in the prior year, the firm posted ($0.16) EPS.August 10, 2024 | marketbeat.comDMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024August 8, 2024 | markets.businessinsider.comDiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial ResultsAugust 7, 2024 | finance.yahoo.comUS proposes barring airlines from charging family seating feesAugust 3, 2024 | ca.finance.yahoo.comDiaMedica Therapeutics (DMAC) Scheduled to Post Quarterly Earnings on WednesdayDiaMedica Therapeutics (NASDAQ:DMAC) will be releasing earnings after the market closes on Wednesday, August 7, Zacks reports.August 2, 2024 | marketbeat.comCraig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)July 30, 2024 | markets.businessinsider.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 22.1% in JuneDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) was the target of a large increase in short interest in the month of June. As of June 30th, there was short interest totalling 156,800 shares, an increase of 22.1% from the June 15th total of 128,400 shares. Based on an average trading volume of 57,500 shares, the short-interest ratio is presently 2.7 days.July 16, 2024 | marketbeat.comKoch Thomas Von Purchases 1,200,000 Shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) StockJuly 2, 2024 | insidertrades.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Major Shareholder Purchases $3,000,000.00 in StockDiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) major shareholder Koch Thomas Von bought 1,200,000 shares of the company's stock in a transaction that occurred on Friday, June 28th. The stock was purchased at an average price of $2.50 per share, for a total transaction of $3,000,000.00. Following the transaction, the insider now owns 5,526,435 shares of the company's stock, valued at $13,816,087.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.July 1, 2024 | marketbeat.comDiaMedica Therapeutics Announces $11.8 Million Private PlacementJune 26, 2024 | businesswire.comDiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into PreeclampsiaJune 26, 2024 | businesswire.comDiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Up 1.1%DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 1.1%May 25, 2024 | marketbeat.comDiaMedica Therapeutics Inc (DMAC)May 14, 2024 | investing.comDiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call TranscriptMay 13, 2024 | seekingalpha.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2024 Earnings Call TranscriptMay 13, 2024 | finance.yahoo.comDMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024May 8, 2024 | msn.comDiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial ResultsMay 8, 2024 | finance.yahoo.comDiaMedica Therapeutics (DMAC) Set to Announce Earnings on WednesdayDiaMedica Therapeutics (NASDAQ:DMAC) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports.May 3, 2024 | marketbeat.comDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024May 2, 2024 | finance.yahoo.comDiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024May 2, 2024 | businesswire.comBullish DiaMedica Therapeutics Insiders Loaded Up On US$15.7m Of StockMay 1, 2024 | finance.yahoo.comDiaMedica Therapeutics (NASDAQ:DMAC) Earns Buy Rating from Analysts at Craig HallumCraig Hallum began coverage on shares of DiaMedica Therapeutics in a report on Wednesday. They issued a "buy" rating and a $8.00 target price on the stock.April 24, 2024 | marketbeat.comDiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 3.6% DiaMedica Therapeutics (NASDAQ:DMAC) Shares Down 3.6%April 24, 2024 | marketbeat.comDiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic StrokeApril 17, 2024 | businesswire.comDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call TranscriptMarch 25, 2024 | finance.yahoo.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 23, 2024 | investorplace.comDiaMedica Therapeutics Inc. (DMAC) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | seekingalpha.com Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. DMAC Media Mentions By Week DMAC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DMAC News Sentiment▼-0.450.49▲Average Medical News Sentiment DMAC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DMAC Articles This Week▼21▲DMAC Articles Average Week Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ironwood Pharmaceuticals News Cullinan Therapeutics News Entrada Therapeutics News Tectonic Therapeutic News Arbutus Biopharma News AnaptysBio News Phathom Pharmaceuticals News ORIC Pharmaceuticals News Exscientia News CorMedix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DMAC) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
